Compare OCC & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCC | MSLE |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | Canada |
| Employees | 348 | 21 |
| Industry | Telecommunications Equipment | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.9M | 154.6M |
| IPO Year | 2001 | N/A |
| Metric | OCC | MSLE |
|---|---|---|
| Price | $16.16 | $9.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 439.7K | 73.3K |
| Earning Date | 06-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,828,590.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $4.02 | $5.44 |
| 52 Week High | $27.98 | $13.39 |
| Indicator | OCC | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 75.47 |
| Support Level | $5.37 | $6.71 |
| Resistance Level | $27.98 | $13.39 |
| Average True Range (ATR) | 2.27 | 0.68 |
| MACD | -0.73 | 0.35 |
| Stochastic Oscillator | 21.88 | 91.12 |
Optical Cable Corp manufactures a broad range of fiber optic and copper data communication cabling and connectivity solutions for the enterprise, wireless carrier, and specialty markets. The Company offers high quality products that operate as a system solution or integrate with other components, including fiber, copper, hybrid cabling, cabinets, racks, enclosures, and deployable solutions for enterprise networks, data centers, residential, campus, Passive Optical LAN installations, and customized applications in military, industrial, mining, petrochemical, renewable energy, and broadcast industries. It operates a single reportable segment covering the design, development, manufacture, and marketing of its cabling and connectivity solutions.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.